Perrigo Q3 net sales fall 5.2%; Core 2026 adjusted EPS outlook cut to $2.15 to $2.35
Perrigo reported third-quarter 2026 net sales of $989 million, down 5.2% from a year earlier, and a GAAP net loss of $27.5 million. The company cut its Core full-year 2026 adjusted EPS outlook to $2.15 to $2.35 from $2.25 to $2.55, citing softer consumer demand, retailer inventory positioning and Europe. It also agreed to sell its Infant Formula business for up to $175 million and expects a $275 million to $375 million impairment loss in the fourth quarter.
Key points
- All In adjusted diluted EPS was $0.60 versus $0.80 a year earlier, down 25.0%; Core adjusted EPS was $0.61, down 9.0%.
- Full-year 2026 Core adjusted EPS outlook is $2.15 to $2.35, down from $2.25 to $2.55; All In outlook is $2.25 to $2.45, up from $2.00 to $2.30 and reflects the Infant Formula divestiture.
- Infant Formula sale carries $40 million in upfront cash at closing plus up to $135 million contingent on net sales milestones through 2030.
- Expected impairment loss of $275 million to $375 million to be recognized in the fourth quarter of 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.